MedTrace Logo

Evaluation of Sedation in COVID-19 ARDS

NCT04667936 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 114

Last updated 2021-07-01

No results posted yet for this study

Summary

This study focuses on the evaluation of various factors repeatedly discussed in relation to the impaired sedation of intubated ventilated COVID-19 patients. The sedation response of \>100 moderately to severely affected COVID-19 ARDS was evaluated. The sedation level was measured at the bedside using the Richmond Agitation and Sedation Scale and ventilator synchrony. The evaluation was performed according to the static evaluation plan with respect to age, storage therapy and organ failure.

Conditions

  • Prone Position
  • Severe Acute Respiratory Syndrome Coronavirus 2
  • Hypnotics and Sedatives
  • Pulmonary Ventilation

Interventions

OTHER

Treatment group

None, solely treatment documentation

Sponsors & Collaborators

  • Goethe University

    lead OTHER

Principal Investigators

  • Armin N Flinspach, MD · KGU

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-01
Primary Completion
2020-12-15
Completion
2021-04-01

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04667936 on ClinicalTrials.gov